Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model

Inanir, Sema; Çöpoğlu, Ümit Sertan; Kokacya, Hanifi; Dokuyucu, Recep; Erbaş, Oytun; Inanir, Ahmet

doi:10.12659/msm.895505

Cited by 12 publications

(3 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And there is also evidence that agomelatine has a unique pharmacological effect and improves depression, depressive symptoms, and sleep cycles in patients with AD [ 37 ]. Agomelatine can improve apathy in frontotemporal dementia [ 38 ]. Yao et al [ 37 ] presented that agomelatine could prevent A β -induced tau phosphorylation and oxidative damage in PC12 cells; agomelatine exerts neuroprotection in AD.…”

Section: Treatment Of Bpsdmentioning

confidence: 99%

Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease

Li¹,

Yao

Tao³

et al. 2021

Behavioural Neurology

View full text Add to dashboard Cite

There are nearly 50 million Alzheimer’s disease (AD) patients worldwide, 90% of whom develop behavioral and psychological symptoms of dementia (BPSD), which increase the mortality rate of patients, and impose an economic and care burden on families and society. As a neurotransmitter and neuromodulator, serotonin is involved in the regulation of psychoemotional, sleep, and feeding functions. Accumulating data support the importance of serotonin in the occurrence and development of BPSD. Studies have shown that reduction of serotonin receptors can increase depression and mental symptoms in AD patients. At present, there is no drug treatment for AD approved by the US Food and Drug Administration. Among them, agomelatine, as a new type of antidepressant, can act on serotonin 2 receptors to improve symptoms such as depression and anxiety. At present, research on BPSD is still in the preliminary exploratory stage, and there are still a lot of unknowns. This review summarizes the relationship between serotonin 2 receptors, agomelatine, and BPSD. It provides a new idea for the study of the pathogenesis and treatment of BPSD.

show abstract

Section: Treatment Of Bpsdmentioning

confidence: 99%

Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease

Li¹,

Yao

Tao³

et al. 2021

Behavioural Neurology

View full text Add to dashboard Cite

show abstract

“…AGM was reported to reduce inflammation and boost antioxidant capacity in motor neurons in the ischemia-reperfusion model [36]. AGM was found to boost antioxidant capacity in psychosis-relevant behavior model [37]. AGM has been found to specifically boost antioxidant capacity in various areas of the brain [18,36].…”

Section: Discussionmentioning

confidence: 99%

Agomelatine protects hippocampal neurons against doxorubicin induced toxicity

Betul Danısman,

Betul Cicek

2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

Doxorubicin (DOX) is a powerful chemotherapy drug used in numerous cancer treatments, known to causes neurotoxicity and impair cognitive function in cancer patients. The main mechanism thought to be responsible for the neuronal damage related to chemotherapy is oxidative stress. Agomelatine (AGM) has recently been identified as a neuroprotective agent against toxicity and the effect of AGM on DOX-induced neurotoxicity was investigated in this study. In order to evaluate the effect of AGM on oxidative stress and apoptosis, malondialdehyde (MDA), lactate dehydrogenase (LDH), superoxide dismutase (SOD), catalase (CAT), and Caspase-3 expression were analyzed in the HT-22 cell line. AGM considerably reduced oxidative damage due to DOX in vitro. MDA and Caspase-3 were considerably higher in the DOX group. These values were dramatically decreased by AGM. AGM greatly increased the CAT and SOD levels when compared to the DOX group. These results suggest that DOX therapy alters antioxidant status in hippocampus, a critical cognition-related region. So if we are aware of the functional effects of DOX, it is possible to avoid some of the disabling side effects of chemotherapy in cancer patients and may prevent these effects with antioxidant agents such as AGM

show abstract

“…on the 2nd day and 40 mg/kg AGO by oral gavage for 7 days. [ 16 ] In the study, a tablet form of AGO was used to mimic the route of administration in humans (orally). Each dose of AGO was freshly prepared and given to rats by oral gavage daily at 8:00.…”

Section: Methodsmentioning

confidence: 99%

Ameliorating effects of agomelatine on testicular and epididymal damage induced by methotrexate in rats

Aslankoç

Özmen

Elli̇dağ

2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

The aim of this study was to investigate the possible prophylactic effects of agomelatine (AGO) against testicular and epididymal damage induced by methotrexate (MTX) in rats. Twenty‐four male Wistar albino rats were divided into three groups: Group I (control group), Group II (MTX group: 20 mg/kg MTX, i.p, single dose), and Group III (MTX+AGO group: 20 mg/kg MTX, i.p, single dose+40 mg/kg AGO; gavage, 7 days). The rats were killed under anesthesia 24 hours after the last AGO application. Testicular and epididymal tissues were bilaterally removed for morphometric, biochemical, pathological, and immunohistochemical analyses. Body, testicular, and epididymal weights were measured. Malondialdehyde (MDA), superoxide dismutase, catalase, and glutathione peroxidase levels were measured in testes. Sperm count, hyperemia, edema, inflammatory reaction, degenerated and necrotic cells were evaluated by histopathological analysis. In addition, inducible nitric oxide synthase (iNOS), granulocyte colony‐stimulating factor (G‐CSF), osteopontin (OPN), and heat shock protein‐70 (HSP70) immune reactions were analyzed in testes and epididymides. Decreased epididymal weights, increased MDA levels, decreased sperm count, hyperemia, edema, inflammatory reaction, and degenerated and necrotic cells were observed in the MTX group. In addition, iNOS, HSP70, G‐CSF, and OPN immune reactions were increased. AGO improved morphometric, biochemical, histopathological, and immunohistochemical findings. The present study confirms that MTX induces testicular and epididymal damage both biochemically and immunohistochemically. However, AGO demonstrated ameliorative effects on both biochemical and pathological findings of the current study.

show abstract

Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model

Cited by 12 publications

References 53 publications

Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease

Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease

Agomelatine protects hippocampal neurons against doxorubicin induced toxicity

Ameliorating effects of agomelatine on testicular and epididymal damage induced by methotrexate in rats

Contact Info

Product

Resources

About